Back to Search
Start Over
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- Source :
- Nature medicine. 21(7)
- Publication Year :
- 2014
-
Abstract
- The cytokine interleukin-12 (IL-12) was thought to have a central role in T cell-mediated responses in inflammation for more than a decade after it was first identified. Discovery of the cytokine IL-23, which shares a common p40 subunit with IL-12, prompted efforts to clarify the relative contribution of these two cytokines in immune regulation. Ustekinumab, a therapeutic agent targeting both cytokines, was recently approved to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders. Here we discuss the therapeutic rationale for targeting these cytokines, the unintended consequences for host defense and tumor surveillance and potential ways in which these therapies can be applied to treat additional immune disorders.
- Subjects :
- Inflammation
business.industry
medicine.medical_treatment
Immunity
Arthritis
General Medicine
Immunotherapy
medicine.disease
Interleukin-12
Interleukin-23
General Biochemistry, Genetics and Molecular Biology
Psoriatic arthritis
Cytokine
Immune system
Immunology
Ustekinumab
Interleukin 23
medicine
Animals
Humans
Immune-mediated inflammatory diseases
Molecular Targeted Therapy
business
Immunologic Surveillance
medicine.drug
Subjects
Details
- ISSN :
- 1546170X
- Volume :
- 21
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Nature medicine
- Accession number :
- edsair.doi.dedup.....b618380030abad053526c4435187fbd3